Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelz^TM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.

CELZ-101, also known as Supercharged Treg Biologic Immunotherapy (ImmCelz^TM), represents a state-of-the-art approach in personalized medicine, utilizing the patient's own regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells. This innovative therapy is based on a proprietary process that not only expands Tregs but also enhances their functionality, offering a promising solution to reduce the need for lifelong immunosuppression.

Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies. This important milestone propels us closer to offering a lasting solution for those grappling with the everyday hurdles of brittle Type 1 diabetes, marked by erratic fluctuations in glucose levels. It harmonizes with our mission to better patients' lives through the forefront of regenerative medicine. "

Dr. Courtney Bartlett, DNP, AGACNP-BC, CCRP, Director of Clinical Development, commented, "The development of CELZ-101 is a major step forward in the realm of cell-based immunotherapy. It addresses the critical need for more effective treatments in brittle Type 1 diabetes by aiming for operational tolerance in islet cell transplantation, potentially freeing patients from the burden of lifelong immunosuppression. We believe this is the first orphan designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes."

“The Orphan Drug Designation by the FDA highlights CELZ-101's potential to meet a significant unmet need in the prevention of allograft rejection during pancreatic islet cell transplantation which was recently approved by the FDA. This designation provides multiple important benefits to support the therapy's development including tax advantages, user fee exemptions, and the opportunity for market exclusivity following approval,” added Timothy Warbington, CEO of the Company.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is dedicated to progressing CELZ-101 through the necessary regulatory pathways, with the goal of transforming the therapeutic landscape for patients in need of islet transplantation. This achievement underscores the company's dedication to leveraging the natural regenerative capabilities of the human body to create lasting health solutions.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is a biotechnology company dedicated to the advancement of identifying and translating novel, immediately deployable FDA registered, biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ.

Creative Medical Technology Holdings is at the vanguard of regenerative medicine, focusing on the development and commercialization of breakthrough therapies for unmet medical needs. With a robust portfolio of innovative treatments, Creative Medical Technology Holdings is reshaping the future of healthcare by marrying advanced scientific research with the body's natural healing mechanisms.

For further information about the Company, please visit www.creativemedicaltechnology.com.

Special Note Regarding Forward Looking Statements

NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306397066/en/